title: Integrin control of the transforming growth factor-β pathway in glioblastoma.
abstract: Transforming growth factor-β is a central mediator of the malignant phenotype of glioblastoma, the most common and malignant form of intrinsic brain tumours. Transforming growth factor-β promotes invasiveness and angiogenesis, maintains cancer cell stemness and induces profound immunosuppression in the host. Integrins regulate cellular adhesion and transmit signals important for cell survival, proliferation, differentiation and motility, and may be involved in the activation of transforming growth factor-β. We report that αvβ3, αvβ5 and αvβ8 integrins are broadly expressed not only in glioblastoma blood vessels but also in tumour cells. Exposure to αv, β3 or β5 neutralizing antibodies, RNA interference-mediated integrin gene silencing or pharmacological integrin inhibition using the cyclic RGD peptide EMD 121974 (cilengitide) results in reduced phosphorylation of Smad2 in most glioma cell lines, including glioma-initiating cell lines and reduced transforming growth factor-β-mediated reporter gene activity, coinciding with reduced transforming growth factor-β protein levels in the supernatant. Time course experiments indicated that the loss of transforming growth factor-β bioactivity due to integrin inhibition likely results from two distinct mechanisms: an early effect on activation of preformed inactive protein, and second, major effect on transforming growth factor-β gene transcription as confirmed by decreased activity of the transforming growth factor-β gene promoter and decreased transforming growth factor-β(1) and transforming growth factor-β(2) messenger RNA expression levels. In vivo, EMD 121974 (cilengitide), which is currently in late clinical development as an antiangiogenic agent in newly diagnosed glioblastoma, was a weak antagonist of pSmad2 phosphorylation. These results validate integrin inhibition as a promising strategy not only to inhibit angiogenesis, but also to block transforming growth factor-β-controlled features of malignancy including invasiveness, stemness and immunosuppression in human glioblastoma.
authors: Department of Neurology, University Hospital Zurich, Frauenklinikstrasse 26, 8091 Zurich, Switzerland. patrick.roth@usz.ch
authors: Patrick
authors: P
authors: Roth
authors: Manuela
authors: M
authors: Silginer
authors: Simon L
authors: SL
authors: Goodman
authors: Kathy
authors: K
authors: Hasenbach
authors: Svenja
authors: S
authors: Thies
authors: Gabriele
authors: G
authors: Maurer
authors: Peter
authors: P
authors: Schraml
authors: Ghazaleh
authors: G
authors: Tabatabai
authors: Holger
authors: H
authors: Moch
authors: Isabel
authors: I
authors: Tritschler
authors: Michael
authors: M
authors: Weller
mesh_terms: D000818:Animals; D001932:Brain Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D045744:Cell Line, Tumor; D005909:Glioblastoma / Q000188:drug therapy / Q000378:metabolism*; D006801:Humans; D016023:Integrins / Q000037:antagonists & inhibitors / Q000502:physiology*; D051379:Mice; D008819:Mice, Nude; D008907:Mink; D009434:Neural Pathways / Q000502:physiology; D012910:Snake Venoms / Q000494:pharmacology / Q000627:therapeutic use; D053773:Transforming Growth Factor beta1 / Q000037:antagonists & inhibitors / Q000096:biosynthesis* / Q000502:physiology
chemical_list: D016023:Integrins; D012910:Snake Venoms; D053773:Transforming Growth Factor beta1; C422910:Cilengitide